Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals’ Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions

(BUSINESS WIRE)--Diffusion Pharmaceuticals What: AHA Abstract #12341 Oral Presentation – “Evaluation of Trans Sodium Crocetinate on Safety and Exercise Performance in Patients with Peripheral Artery Disease and Intermittent Claudication.”